ArticleBMC immunology2025
Inflammatory tropism in COVID-19: a comparative analysis of Delta and Omicron variants.
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical presentation of COVID-19 varies significantly by viral variant; the Delta variant often causes severe lung inflammation, whereas Omicron tends to result in less severe respiratory disease but may more readily affect other organs. The autoimmune mechanisms behind these variant-specific complications, particularly the potential role of anti-neutrophil cytoplasmic (ANCA) antibodies, are still not well defined. This study investigated myeloperoxidase (MPO), proteinase 3 (PR3), and glomerular basement membrane (GBM) antibodies in patients infected with the Delta and Omicron SARS-CoV-2 variants to evaluate their associations with specific clinical complications, such as renal or respiratory involvement.
methodsSamples were collected during Delta and Omicron outbreaks from hospitalized COVID-19 patients (40 Delta, 40 Omicron) and 40 healthy controls. Serum autoantibodies (MPO, PR3, GBM) were measured via ELISA, and laboratory/clinical data were collected.
resultsAll autoantibody levels remained within normal limits. Despite statistical significance (P < 0.05), effect sizes were small (η²=0.085-0.180). Anti-MPO was highest in the Delta group (1.08 U/mL) vs. Control (0.71 U/mL) and Omicron (0.77 U/mL). Anti-PR3 was lowest in the Delta group (0.83 U/mL) vs. Control (1.52 U/mL). Anti-GBM was lowest in the Omicron group (1.48 U/mL) vs. Control (3.48 U/mL) and Delta (3.10 U/mL). Clinically, the Delta group exhibited significantly lower oxygen saturation (92.28% ± 8.69) than the Omicron group (96.15% ± 2.77; P = 0.009). Markers of inflammation and tissue damage-including C-reactive protein (CRP), lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and coagulation parameters-were markedly elevated in the Delta group compared to the Omicron group (P < 0.001). Conversely, creatinine was significantly higher in the Omicron group (P < 0.001).
conclusionWhile autoantibody levels remained normal, clinical profiles diverged significantly between variants. The Delta variant was associated with heightened systemic inflammation, whereas Omicron was associated with greater organ involvement, suggesting the possibility of distinct pathogenic mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.